• Most Popular
  • Most Shared

Genvec says cancer therapy increases survival; shares up

Thu May 29, 2008 9:15am EDT

Stocks

   

May 29 (Reuters) - Genvec Inc (GNVC.O) said its gene therapy product, TNFerade, increased survival of patients with esophageal cancer longer than comparable studies, sending its shares up 11 percent before the bell.

The company said long-term survival data from the mid-stage trial showed that following treatment with TNFerade and chemoradiation, the median overall survival of patients was 48.4 months. Literature review of comparable studies shows median survival ranging from 9.7 to 18.6 months, it added.

Shares of Genvec, which closed at $1.80 Wednesday on Nasdaq, were trading at $2.00 before the bell. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Jarshad Kakkrakandy)



More from Reuters

Photo

U.S. producer prices jump, factory reports mixed

WASHINGTON (Reuters) - U.S. producer prices jumped a surprising 1.8 percent last month and industrial output rose firmly, leading to inflation jitters in financial markets. | Video

» More Top News
The Boeing 787 Dreamliner aircraft is surrounded by employees and special guests during its world premiere outside the Boeing assembly plant in Everett, Washington, in this July 8, 2007 file photo. REUTERS/Robert Sorbo/Files

Dreamliner set for test flight

Boeing's fuel-efficient 787 will take off on its first test flight, nearly two and a half years behind schedule. But the hurdles aren't over.  Full Article 

Aerospace and Defense Summit
Demonstrator holds a signboard with a slogan "Bla bla bla ACT NOW" during a rally outside the UN Climate Change Conference in Copenhagen, December 12, 2009. Credit: REUTERS/Christian Charisius

Rewarding polluters

A climate change scientist blasts proposals for a cap and trade system, arguing that it allows dirty industries to continue polluting, instead of rewarding innovation.  Full Article 

Climate Conference